Medtronic plc (MDT) Stock

About Medtronic plc

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.

Medtronic plc is led by CEO Geoffrey Straub Martha, employs 95,000 people, headquartered in Galway, US, publicly traded since 1973.

Medtronic plc (MDT) stock trades at $87.54 with a market capitalization of $112.06B. The stock is valued at a price-to-earnings (P/E) ratio of 21.27, price-to-book of 2.00, price-to-sales of 2.87. Over the past 52 weeks the stock has ranged between $73.31 and $106.33, and currently trades 17.7% below its 52-week high. It pays a dividend yielding 3.49%.

On profitability, Medtronic plc generates a return on equity (ROE) of 9.39%, return on capital employed of 12.34%, an operating margin of 17.76%, a net profit margin of 13.20%.

In its most recent fiscal year, Medtronic plc reported annual revenue of $36.4B, net profit of $4.8B, revenue has compounded at 3.8% a year over the last five years, profit at 5.9% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.57, a current ratio of 1.85, total assets of $91.7B, $2.2B in cash and equivalents.

MDT has an average daily trading volume of 10,067,290 shares, a beta of 0.60 (less volatile than the overall market).

Official website: www.medtronic.com